The Israeli company, which is developing drugs for the treatment of Covid respiratory failure and suicidal bipolar depression, has begun trading on Nasdaq as NrX Pharmaceuticals.
Israeli Pharma Firm NeuroRx Completes SPAC Merger at $1.5B Valuation
By NoCamels Team
May 31, 2021 2 minutes
Health & ScienceNews Briefs
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses CDC/ Alissa Eckert, MS; Dan Higgins, MAM. Wikimedia Commons
Israeli clinical-stage small molecule pharmaceutical company NeuroRx has announced the completion of a merger with Big Rock Partners Acquisition Corporation, a special purpose acquisition (SPAC) company. The company will trade on the NASDAQ as NRXP.
The deal is estimated to be worth a $1.5 billion valuation, the Haifa-based company said.
Founded in 2014, NeuroRx is a clinical-stage small molecule pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary disease. The company’s two primary medicines are ZYESAMI (aviptadil), an application for COVID-19-related